(NASDAQ: CRBP) Corbus Pharmaceuticals Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.71%.
Corbus Pharmaceuticals Holdings's earnings in 2026 is -$84,528,000.On average, 12 Wall Street analysts forecast CRBP's earnings for 2026 to be -$87,291,853, with the lowest CRBP earnings forecast at -$103,496,263, and the highest CRBP earnings forecast at -$60,307,973. On average, 11 Wall Street analysts forecast CRBP's earnings for 2027 to be -$96,802,171, with the lowest CRBP earnings forecast at -$133,637,280, and the highest CRBP earnings forecast at -$45,328,250.
In 2028, CRBP is forecast to generate -$104,024,305 in earnings, with the lowest earnings forecast at -$135,997,721 and the highest earnings forecast at -$53,888,092.